Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $207.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by Stifel Nicolaus from $200.00 to $207.00 in a report published on Friday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on ASND. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Wedbush reiterated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. Citigroup boosted their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $2.23 during trading on Friday, reaching $126.51. The stock had a trading volume of 1,448,861 shares, compared to its average volume of 450,130. The business’s 50-day moving average price is $132.30 and its 200-day moving average price is $132.70. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00. The company has a market cap of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the third quarter worth approximately $60,000. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares during the period. Bessemer Group Inc. grew its position in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares during the last quarter. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at $205,000. Finally, Rhumbline Advisers raised its position in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.